Holobiome is a biotechnology company - designated a Cambridge MA JLab Alumni - developing microbiome-based therapeutics for diseases of the central and enteric nervous systems. All humans have an enormous community of bacteria - designated the microbiome - known to influence many components of human condition: metabolism, susceptibility to disease, and the immune response. Recent evidence from work undertaken by Hololbiome founders suggest that the microbiome also influences diseases of the nervous system. The lead products of Holobiome, therefore, consist of naturally occurring bacteria that modulate host neurotransmission and that may have broad therapeutic utility. The company's platform therefore is designed to deliver microbiome-based therapeutics to patients suffering from depression, anxiety and other mental health problems.
